[18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: An in vitro study

British Journal of Cancer

Volumn 99, Issue 3, 2008, Pages 481-487

  Direcks, W G E ^a   Berndsen, S C ^a   Proost, N ^a   Peters, G J ^a   Balzarini, J ^b   Spreeuwenberg, M D ^a   Lammertsma, A A ^a   Molthoff, C F M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

18F FDG; 18F FLT; Breast cancer cells; Chemotherapy; PET; Thymidine kinase

Indexed keywords

3' DEOXY 3' FLUOROTHYMIDINE F 18; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; PACLITAXEL; RADIOPHARMACEUTICAL AGENT; THYMIDINE KINASE 1; ANTINEOPLASTIC AGENT; THYMIDINE; THYMIDINE KINASE;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CELL CYCLE PHASE; CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; BREAST TUMOR; CELL CYCLE; ENZYMOLOGY; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; DOXORUBICIN; FLUORODEOXYGLUCOSE F18; FLUOROURACIL; HUMANS; PACLITAXEL; THYMIDINE; THYMIDINE KINASE;

EID: 48349117120     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604523     Document Type: Article

References (32)

1. Ackland SP, Clarke SJ, Beale P, Peters GJ (2002) Thymidylate synthase inhibitors. Cancer Chemother Biol Response Modif 20: 1-36
2. Balzarini J, Hernandez AI, Roche P, Esnouf R, Karlsson A, Camarasa MJ, Perez-Perez MJ (2003) Non-nucleoside inhibitors of mitochondrial thymidine kinase (TK-2) differentially inhibit the closely related herpes simplex virus type 1 TK and Drosophila melanogaster multifunctional deoxynucleoside kinase. Mol Pharmacol 63: 263-270
3. Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q, Luthra SK, Brady F, Price PM, Aboagye EO (2003) 3′-deoxy-3′-[18F] fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 63: 3791-3798
4. Barthel H, Perumal M, Latigo J, He Q, Brady F, Luthra SK, Price PM, Aboagye EO (2005) The uptake of 3′-deoxy-3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging 32: 257-263
5. Chang ZF, Huang DY, Hsue NC (1994) Differential phosphorylation of human thymidine kinase in proliferating and M phase-arrested human cells. J Biol Chem 269: 21249-21254
6. de Bruin M, van Capel T, van der Born K, Kruyt FA, Fukushima M, Hoekman K, Pinedo HM, Peters GJ (2003) Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity. Br J Cancer 88: 957-964
7. Direcks WGE, Lammertsma AA, Molthoff CFM (2006) 3′-Deoxy-3′- fluorothymidine as a tracer of proliferation in positron emission tomography. In: Deoxynucleoside Analogs in Cancer Therapy, Peters GJ (ed), pp 441-462. Totowa, NJ: Humana Press Inc.
8. Dittmann H, Dohmen BM, Kehlbach R, Bartusek G, Pritzkow M, Sarbia M, Bares R (2002) Early changes in [18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 29: 1462-1469
9. Engles JM, Quarless SA, Mambo E, Ishimori T, Cho SY, Wahl RL (2006) Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy. J Nucl Med 47: 603-608
10. Eriksson S, Munch-Petersen B, Johansson K, Eklund H (2002) Structure and function of cellular deoxyribonucleoside kinases. Cell Mol Life Sci 59: 1327-1346
11. Honkoop AH, Luykx-de Bakker SA, Hoekman K, Meyer S, Meyer OW, van Groeningen CJ, van Diest PJ, Boven E, van der Wall E, Giaccone G, Wagstaff J, Pinedo HM (1999) Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer. Oncologist 4: 106-111
12. Kavallaris M, Verrills NM, Hill BT (2001) Anticancer therapy with novel tubulin-interacting drugs. Drug Resist Updat 4: 392-401
13. Kenny LM, Vigushin DM, Al Nahhas A, Osman S, Luthra SK, Shousha S, Coombes RC, Aboagye EO (2005) Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine- positron emission tomography imaging: evaluation of analytical methods. Cancer Res 65: 10104-10112
14. Kralovanszky J, Prajda N, Kerpel-Fronius S, Bagrij T, Kiss E, Peters GJ (1993) Biochemical consequences of 5-fluorouracil gastrointestinal toxicity in rats; effect of high-dose uridine. Cancer Chemother Pharmacol 32: 243-248
15. Machulla H-J, Blocher A, Kuntzsch M, Piert M, Wie R, Grierson JR (2000) Simplified labeling approach for synthesizing 3′-deoxy-3′-[18F] fluorothymidine ([18F]FLT). J Radioanalyt Nucl Chem 243: 843-846
16. Maschauer S, Prante O, Hoffmann M, Deichen JT, Kuwert T (2004) Characterization of 18F-FDG uptake in human endothelial cells in vitro. J Nucl Med 45: 455-460
17. Mirjolet JF, Didelot C, Barberi-Heyob M, Merlin JL (2002) G(1)/S but not G(0)/G(1)cell fraction is related to 5-fluorouracil cytotoxicity. Cytometry 48: 6-13
18. Munch-Petersen B, Cloos L, Tyrsted G, Eriksson S (1991) Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem 266: 9032-9038
19. Potter AJ, Rabinovitch PS (2005) The cell cycle phases of DNA damage and repair initiated by topoisomerase II-targeting chemotherapeutic drugs. Mutat Res 572: 27-44
20. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL (2002) Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 43: 1210-1217
21. Sherley JL, Kelly TJ (1988) Regulation of human thymidine kinase during the cell cycle. J Biol Chem 263: 8350-8358
22. Shields AF (2006) Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology. Mol Imaging Biol 8: 141-150
23. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O, Mangner TJ (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4: 1334-1336
24. Sundseth R, Joyner SS, Moore JT, Dornsife RE, Dev IK (1996) The anti-human immunodeficiency virus agent 3′-fluorothymidine induces DNA damage and apoptosis in human lymphoblastoid cells. Antimicrob Agents Chemother 40: 331-335
25. Temmink OH, Hoebe EK, Van der Born K, Ackland SP, Fukushima M, Peters GJ (2007) Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells. Br J Cancer 96: 231-240
26. Twisk JW (2006) Multilevel analysis in longitudinal studies. In Applied Multilevel Analysis, pp 86-107. Cambridge: Cambridge University Press
27. van der Wilt CL, Backus HH, Smid K, Comijn L, Veerman G, Wouters D, Voorn DA, Priest DG, Bunni MA, Mitchell F, Jackman AL, Jansen G, Peters GJ (2001) Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. Cancer Res 61: 3675-3681
28. van Waarde A, Been LB, Ishiwata K, Dierckx RA, Elsinga PH (2006) Early response of sigma-receptor ligands and metabolic PET tracers to 3 forms of chemotherapy: an in vitro study in glioma cells. J Nucl Med 47: 1538-1545
29. Wang TH, Wang HS, Soong YK (2000) Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 88: 2619-2628
30. Warburg O, Wind F, Negalein E (1927) The metabolism of tumours in the body. J Physiol 8: 519-530
31. Weigelt B, Peterse JL, 't Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5: 591-602
32. Yau K, Price P, Pillai RG, Aboagye E (2006) Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors. Eur J Nucl Med Mol Imaging 33: 981-987